Enliven Therapeutics (NASDAQ:ELVN) Trading Up 21.1% – Here’s Why

Shares of Enliven Therapeutics, Inc. (NASDAQ:ELVN) were up 21.1% during trading on Friday . The stock traded as high as $26.15 and last traded at $28.1640. Approximately 688,138 shares changed hands during mid-day trading, a decline of 65% from the average daily volume of 1,991,956 shares. The stock had previously closed at $23.25.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Enliven Therapeutics in a research note on Wednesday, October 8th. Wall Street Zen upgraded Enliven Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, November 15th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $41.00.

Enliven Therapeutics Trading Up 11.8%

The stock has a fifty day simple moving average of $19.07 and a 200-day simple moving average of $19.96. The company has a market capitalization of $1.54 billion, a PE ratio of -14.13 and a beta of 0.41.

Enliven Therapeutics (NASDAQ:ELVN) last issued its earnings results on Thursday, November 13th. The company reported ($0.32) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.11. As a group, equities research analysts predict that Enliven Therapeutics, Inc. will post -1.95 EPS for the current year.

Insider Transactions at Enliven Therapeutics

In other news, COO Anish Patel sold 6,663 shares of the company’s stock in a transaction on Monday, December 8th. The shares were sold at an average price of $21.02, for a total value of $140,056.26. Following the completion of the transaction, the chief operating officer owned 263,311 shares in the company, valued at approximately $5,534,797.22. This represents a 2.47% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Joseph P. Lyssikatos sold 5,000 shares of Enliven Therapeutics stock in a transaction on Friday, December 19th. The stock was sold at an average price of $16.84, for a total transaction of $84,200.00. Following the sale, the insider owned 897,688 shares in the company, valued at $15,117,065.92. This represents a 0.55% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 68,330 shares of company stock worth $1,434,762. 25.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in ELVN. Commodore Capital LP increased its position in Enliven Therapeutics by 0.4% during the second quarter. Commodore Capital LP now owns 4,692,809 shares of the company’s stock worth $94,138,000 after buying an additional 17,809 shares during the period. Polar Capital Holdings Plc increased its holdings in shares of Enliven Therapeutics by 1.5% in the 3rd quarter. Polar Capital Holdings Plc now owns 3,095,007 shares of the company’s stock valued at $63,355,000 after acquiring an additional 44,713 shares during the period. Vanguard Group Inc. increased its holdings in shares of Enliven Therapeutics by 5.9% in the 3rd quarter. Vanguard Group Inc. now owns 2,553,014 shares of the company’s stock valued at $52,260,000 after acquiring an additional 142,378 shares during the period. Vestal Point Capital LP raised its position in Enliven Therapeutics by 364.0% in the 3rd quarter. Vestal Point Capital LP now owns 1,160,000 shares of the company’s stock valued at $23,745,000 after purchasing an additional 910,000 shares during the last quarter. Finally, Duquesne Family Office LLC boosted its stake in Enliven Therapeutics by 104.6% during the 3rd quarter. Duquesne Family Office LLC now owns 947,405 shares of the company’s stock worth $19,393,000 after purchasing an additional 484,405 shares during the period. Hedge funds and other institutional investors own 95.08% of the company’s stock.

About Enliven Therapeutics

Enliven Therapeutics is a clinical-stage biotechnology company focused on developing small-molecule therapies that harness induced proximity mechanisms to selectively target and degrade disease-causing proteins in cancer. Leveraging its proprietary Induced Proximity platform, the company designs molecular glues and related modalities to recruit endogenous cellular machinery for targeted protein degradation, with the goal of treating malignancies driven by so-called “undruggable” oncogenic factors.

The company’s pipeline comprises several early-stage programs directed at key oncogenic drivers across hematologic and solid tumor indications.